Long-term efficacy and influencing factors of extended thymectomy for myasthenia gravis with thymic atrophy
- VernacularTitle:胸腺扩大切除术治疗重症肌无力合并胸腺萎缩的远期疗效及其影响因素分析
- Author:
Taiming ZHANG
1
;
Xiaohe ZHANG
2
;
Cheng SHEN
1
;
Shulin ZHAO
1
;
Xiandong HE
1
;
Shaolin TAO
1
;
Qunyou TAN
1
Author Information
1. Department of Thoracic Surgery, Daping Hospital, Army Medical University, Chongqing, 400042, P. R. China
2. Hebei Provincial Myasthenia Gravis Diagnosis and Treatment Center, Shijiazhuang People Hospital, Shijiazhuang, 050030, P. R. China
- Publication Type:Journal Article
- Keywords:
Myasthenia gravis;
thymic atrophy;
thymectomy;
long-term efficacy
- From:
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery
2023;30(06):848-852
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze the surgical efficacy and influencing factors of myasthenia gravis (MG) patients with thymic atrophy after thymectomy. Methods The clinical data of MG patients with thymic atrophy undergoing thymectomy between October 2014 and May 2018 in Daping Hospital of Army Medical University and Shijiazhuang People Hospital were retrospectively analyzed. Results A total of 71 patients were collected, including 40 males and 31 females with a mean age of 45.17±12.42 years. All patients received the surgery successfully. After the surgery, 20 (28.17%) patients were stable remission, 12 (16.90%) patients were minimal manifestation status,19 (26.76%) patients were improved, 5 (7.04%) patients showed no change, 3 (4.23%) patients were worsened, 10 (14.08%) patients were exacerbated and 2 (2.82%) patients were dead. Multivariate logistic regression analysis showed that the preoperative illness duration (OR=4.61, 95%CI 1.13-18.85, P=0.03), and postoperative pyridostigmine combined with immunosuppressive (OR=0.12, 95%CI 0.03-0.45, P=0.00) were independent risk factors for long-term efficacy of thymectomy for MG patients with thymic atrophy. Conclusion Early surgery after diagnosis of MG and postoperative pyridostigmine combined with immunosuppressive treatment is beneficial to the prognosis of MG patients with thymic atrophy.
